What is the preferred medication between trazosin (trazodone) and prazosin for treating post-traumatic stress disorder (PTSD)-related nightmares?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prazosin vs Trazodone for PTSD-Related Nightmares

Prazosin is the preferred medication for treating PTSD-related nightmares with Level A evidence from the American Academy of Sleep Medicine, while trazodone has more limited supporting evidence. 1

First-Line Treatment Approach

Non-Pharmacological Options

  • Image Rehearsal Therapy (IRT) should be attempted first before medication
  • If IRT is insufficient after 4-6 weeks, pharmacological treatment should be added

Pharmacological Treatment

Prazosin (First-Line)

  • Dosing protocol:

    • Start at 1 mg at bedtime
    • Titrate by 1-2 mg every 3-7 days
    • Target effective dose: 3 mg (range 1-10+ mg)
    • Some patients may require higher doses (up to 30-45 mg in treatment-resistant cases)
    • Consider twice-daily dosing for some patients 1
  • Efficacy:

    • Level A evidence (highest recommendation) from American Academy of Sleep Medicine 1
    • Reduces nightmare frequency by over 50% compared to 15% with placebo 2
    • Therapeutic benefit can occur with doses as low as 1 mg daily 3
    • Suppression of nightmare symptoms may occur within one week of initiation 3
  • Monitoring:

    • Watch for orthostatic hypotension, especially after first dose
    • Monitor blood pressure during treatment 1

Trazodone (Alternative Option)

  • Dosing:

    • Effective dose range: 50-200 mg nightly (for 70% of patients)
    • Mean effective dose: 212 mg/day 2, 4
  • Efficacy:

    • Decreased nightmare frequency from 3.3 to 1.3 nights/week in 72% of patients 4
    • Helps with sleep onset (92% of patients) and sleep maintenance (78% of patients) 4
    • Lower level of evidence compared to prazosin 1
  • Side effects:

    • 60% of patients experience side effects, particularly daytime sedation or dizziness
    • 12% reported priapism in one study (higher than expected) 4
    • Other side effects include dry mouth/sinuses, muscle pain, and agitation 2

Clinical Decision Algorithm

  1. Start with non-pharmacological treatment (IRT)
  2. If IRT is insufficient after 4-6 weeks, add pharmacological treatment:
    • First choice: Prazosin (start at 1 mg, titrate as needed)
    • If prazosin is contraindicated or not tolerated: Consider trazodone
  3. If combined approach fails:
    • Consider clonidine (0.1-0.6 mg) or atypical antipsychotics as adjunctive therapy 1

Important Considerations and Pitfalls

  • Avoid underdosing prazosin - many patients require doses higher than initially prescribed
  • Monitor for orthostatic hypotension with prazosin, especially after first dose
  • Be vigilant about priapism with trazodone - directly ask male patients about this side effect
  • Avoid medications specifically not recommended for nightmare disorder:
    • Clonazepam (ineffective)
    • Venlafaxine (not recommended) 1
  • Don't rely solely on pharmacological treatment - combination with behavioral approaches is optimal
  • Don't discontinue treatment prematurely - continued therapy may be necessary for sustained benefit

Prazosin demonstrates superior efficacy and safety profile compared to trazodone for PTSD-related nightmares, with stronger evidence supporting its use as first-line pharmacological treatment when medication is needed 1, 5.

References

Guideline

Sleep Disorder Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Prazosin for treatment of nightmares related to posttraumatic stress disorder.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.